Characterization of site-specific O-glycan structures within the mucin-like domain of α-dystroglycan from human skeletal muscle

Glycobiology

Volumn 20, Issue 9, 2010, Pages 1160-1169

  Nilsson, Johanna ^a,b   Nilsson, Jonas ^a   Larson, Göran ^a   Grahn, Ammi ^a  

^a Institute of Biomedicine   (Germany)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

dystroglycan; glycopeptide; glycoproteomics; glycosylation; mass spectrometry

Indexed keywords

ALPHA DYSTROGLYCAN; ASPARTYLPROLYLVALYLPROLYLGLYCYLLYSYLPROLYLTHREONYLVALYLTHREONYLISOLEUCYLARGININE; GLYCAN; GLYCOPEPTIDE; ISOLEUCYLARGINYLTHREONYLTHREONYLTHREONYLSERYLGLYCYLVALYLPROLYLARGININE; LEUCYLGLUTAMYLTHREONYLALANYLSERYLPROLYLPROLYLTHREONYLARGININE; MUCIN; PEPTIDE; PROLYLVALYLPROLYLGLYCYLLYSYLPROLYLTHREONYLVALYLTHREONYLISOLEUCYLARGININE; PROLYLVALYLPROLYLGLYCYLLYSYLPROLYLTHREONYLVALYLTHREONYLISOLEUCYLARGINYLTHREONYLARGININE; SIALIC ACID; THREONYLPROLYLARGINYLPROLYLVALYLPROLYLARGININE; THREONYLTHREONYLTHREONYLSERYLGLYCYLVALYLPROLYLARGININE; UNCLASSIFIED DRUG; VALYLTHREONYLTHREONYLLYSYLVALYLSERYLISOLEUCYLTHREONYLARGININE;

ARTICLE; CARBOXY TERMINAL SEQUENCE; GLYCOSYLATION; HUMAN; HUMAN TISSUE; LIQUID CHROMATOGRAPHY; MALE; PRIORITY JOURNAL; PROTEIN STRUCTURE; SIALYLATION; SKELETAL MUSCLE; TANDEM MASS SPECTROMETRY;

AMINO ACID SEQUENCE; CARBOHYDRATE SEQUENCE; CATALYTIC DOMAIN; DYSTROGLYCANS; GLYCOSYLATION; HUMANS; MOLECULAR SEQUENCE DATA; MUCINS; MUSCLE, SKELETAL; N-ACETYLNEURAMINIC ACID; PEPTIDE MAPPING; POLYSACCHARIDES; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN STRUCTURE, TERTIARY; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY;

EID: 77955440095     PISSN: 09596658     EISSN: 14602423     Source Type: Journal    
DOI: 10.1093/glycob/cwq082     Document Type: Article

References (39)

1. Aguilan JT, Sundaram S, Neives E, Stanley P. 2009. Mutational and functional analysis of LARGE in a novel CHO glycosylation mutant. Glycobiology. 19:971-986.
2. Andersen DC, Bridges T, Gawlitzek M, Hoy C. 2000. Multiple cell culture factors can affect the glycosylation of Asn-184 in CHO-produced tissue-type plasminogen activator. Biotechnol Bioeng. 70(1):25-31.
3. Barresi R, Campbell KP. 2006. Dystroglycan: From biosynthesis to pathogen-esis of human disease. J Cell Sci. 119:199-207.
4. Barresi R, Michele DE, Kanagawa M, Harper HA, Dovico SA, Satz JS, Moore SA, Zhang W, Schachter H, Dumanski JP, et al. 2004. LARGE can functionally bypass alpha-dystroglycan glycosylation defects in distinct congenital muscular dystrophies. Nat Med. 10(7):696-703.
5. Beltran-Valero de Bernabe D, Voit T, Longman C, Steinbrecher A, Straub V, Yuva Y, Herrmann R, Sperner J, Korenke C, Diesen C, et al. 2004. Mutations in the FKRP gene can cause muscle-eye-brain disease and Walker-Warburg syndrome. J Med Genet. 41(5):e61.
6. Brancaccio A, Schulthess T, Gesemann M, Engel J. 1995. Electron microscopic evidence for a mucin-like region in chick muscle alpha-dystroglycan. FEBS Lett. 368(1):139-142.
7. Breloy I, Schwientek T, Gries B, Razawi H, Macht M, Albers C, Hanisch FG. 2008. Initiation of mammalian O-mannosylation in vivo is independent of a consensus sequence and controlled by peptide regions within and upstream of the alpha-dystroglycan mucin domain. J Biol Chem. 283(27):18832-18840.
8. BrockingtonM, Blake DJ, Prandini P, Brown SC, Torelli S,Benson MA, Ponting CP, EstournetB, Romero NB, MercuriE,et al. 2001. Mutations inthe fukutin-related protein gene (FKRP) cause a form of congenital muscular dystrophy with secondary laminin alpha2 deficiency and abnormal glycosylation of al-pha-dystroglycan. Am J Hum Genet. 69(6):1198-1209.
9. Chiba A, Matsumura K, Yamada H, Inazu T, Shimizu T, Kusunoki S, Kanazawa I, Kobata A, Endo T. 1997. Structures of sialylated O-linked oligosacchar-ides of bovine peripheral nerve alpha-dystroglycan. The role of a novel O-mannosyl-type oligosaccharide in the binding of alpha-dystroglycan with laminin. J Biol Chem. 272(4):2156-2162.
10. Combs AC, Ervasti JM. 2005. Enhanced laminin binding by alpha-dystroglycan after enzymatic deglycosylation. Biochem J. 390:303-309.
11. Endo T, Toda T. 2003. Glycosylation in congenital muscular dystrophies. Biol Pharm Bull. 26(12):1641-1647.
12. Ervasti JM, Burwell AL, Geissler AL. 1997. Tissue-specific heterogeneity in alpha-dystroglycan sialoglycosylation. Skeletal muscle alpha-dystroglycan is a latent receptor for Vicia villosa agglutinin b4 masked by sialic acid modification. J Biol Chem. 272(35):22315-22321.
13. Gawlitzek M,ValleyU, Nimtz M, WagnerR,Conradt HS. 1995. Characterization of changes in the glycosylation pattern of recombinant proteins from BHK-21 cells due todifferent culture conditions. JBiotechnol. 42(2):117-131.
14. Godfrey C, Clement E, Mein R, Brockington M, Smith J, Talim B, Straub V, Robb S, Quinlivan R, Feng L, et al. 2007. Refining genotype phenotype correlations in muscular dystrophies with defective glycosylation of dystro-glycan. Brain. 130:2725-2735.
15. Huddleston MJ, Bean MF, Carr SA. 1993. Collisional fragmentation of glycopep-tidesbyelectrospray ionization LC/MS and LC/MS/MS: Methods for selective detection of glycopeptides in protein digests. Anal Chem. 65(7):877-884.
16. Ibraghimov-Beskrovnaya O, Ervasti JM, Leveille CJ, Slaughter CA, Sernett SW, Campbell KP. 1992. Primary structure of dystrophin-associated glycoproteins linking dystrophin to the extracellular matrix. Nature. 355(6362):696-702.
17. Ibraghimov-Beskrovnaya O, Milatovich A, Ozcelik T, Yang B, Koepnick K, Francke U, Campbell KP. 1993. Human dystroglycan: skeletal muscle cDNA, genomic structure, origin of tissue specific isoforms and chromosomal localization. Hum Mol Genet. 2(10):1651-1657.
18. Jenkins N, Curling EM. 1994. Glycosylation of recombinant proteins: problems and prospects. Enzyme Microb Technol. 16(5):354-364.
19. Jenkins N, Parekh RB, James DC. 1996. Getting the glycosylation right: implications for the biotechnology industry. Nat Biotechnol. 14(8):975-981.
20. Jimenez-Mallebrera C, Torelli S, Feng L, Kim J, Godfrey C, Clement E, Mein R, Abbs S, Brown SC, Campbell KP, et al. 2008. A comparative study of alpha-dystroglycan glycosylation in dystroglycanopathies suggests that the hypo-glycosylation of alpha-dystroglycan does not consistently correlate with clinical severity. Brain Pathol.
21. Jimenez-Mallebrera C, Torelli S, Feng L, Kim J, Godfrey C, Clement E, Mein R, Abbs S, Brown SC, Campbell KP, et al. 2009. A comparative study of alpha-dystroglycan glycosylation in dystroglycanopathies suggests that the hypoglycosylation of alpha-dystroglycan does not consistently correlate with clinical severity. Brain Pathol. 19 (4):596-611.
22. Leschziner A, Moukhles H, Lindenbaum M, Gee SH, Butterworth J, Campbell KP, Carbonetto S. 2000. Neural regulation of alpha-dystroglycan biosynthesis and glycosylation in skeletal muscle. J Neurochem. 74(1):70-80.
23. Manya H, Suzuki T, Akasaka-Manya K, Ishida HK, Mizuno M, Suzuki Y, Inazu T, Dohmae N, Endo T. 2007. Regulation of mammalian protein O-mannosylation: Preferential amino acid sequence for O-mannose modification. J Biol Chem. 282(28):20200-20206.
24. McDearmon EL, Combs AC, Ervasti JM. 2001. Differential Vicia villosa agglutinin reactivity identifies three distinct dystroglycan complexes in skeletal muscle. J Biol Chem. 276(37):35078-35086.
25. McDearmon EL, Combs AC, Ervasti JM. 2003. Core 1 glycans on alpha-dystroglycan mediate laminin-induced acetylcholine receptor clustering but not laminin binding. J Biol Chem. 278(45):44868-44873.
26. McDearmon EL, Combs AC, Sekiguchi K, Fujiwara H, Ervasti JM. 2006. Brain alpha-dystroglycan displays unique glycoepitopes and preferential binding to laminin-10/11. FEBS Lett. 580(14):3381-3385.
27. Mercuri E, Brockington M, Straub V, Quijano-Roy S, Yuva Y, Herrmann R, Brown SC, Torelli S, Dubowitz V, Blake DJ, et al. 2003. Phenotypic spectrum associated with mutations in the fukutin-related protein gene. Ann Neurol. 53:537-542.
28. Mercuri E, D'Amico A, Tessa A, Berardinelli A, Pane M, Messina S, van Reeuwijk J, Bertini E, Muntoni F, Santorelli FM. 2006a. POMT2 mutation in a patient with 'MEB-like' phenotype. Neuromuscul Disord. 16 (7)446-448.
29. Mercuri E, Topaloglu H, Brockington M, Berardinelli A, Pichiecchio A, Santorelli F, Rutherford M, Talim B, Ricci E, Voit T, et al. 2006b. Spectrum of brain changes in patients with congenital muscular dystrophy and FKRP gene mutations. Arch Neurol. 63(2):251-257.
30. Michele DE, Barresi R, Kanagawa M, Saito F, Cohn RD, Satz JS, Dollar J, Nishino I, Kelley RI, Somer H, et al. 2002. Post-translational disruption of dystroglycan-ligand interactions in congenital muscular dystrophies. Nature. 418(6896)417-422.
31. Nilsson J, Ruetschi U, Halim A, Hesse C, Carlsohn E, Brinkmalm G, Larson G. 2009. Enrichment of glycopeptides for glycan structure and attachment site identification. Nat Methods. 6(11):809-811.
32. Patnaik SK, Stanley P. 2005. Mouse large can modify complex N-and mucin O-glycans on alpha-dystroglycan to induce laminin binding. J Biol Chem. 280(21):20851-20859.
33. Poppe M, Cree L, Bourke J, Eagle M, Anderson LV, Birchall D, Brockington M, Buddles M, Busby M, Muntoni F, et al. 2003. The phenotype of limb-girdle muscular dystrophy type 2I. Neurology. 60(8):1246-1251.
34. Smalheiser NR, Haslam SM, Sutton-Smith M, Morris HR, Dell A. 1998. Structural analysis of sequences O-linked to mannose reveals a novel Lewis X structure in cranin (dystroglycan) purified from sheep brain. J Biol Chem. 273(37):23698-23703.
35. van Reeuwijk J, Janssen M, van den Elzen C, Beltran-Valero de Bernabe D, Sabatelli P, Merlini L, Boon M, Scheffer H, Brockington M, Muntoni F, et al. 2005. POMT2 mutations cause alpha-dystroglycan hypoglycosylation and Walker-Warburg syndrome. J Med Genet. 42(12):907-912.
36. van Reeuwijk J, Maugenre S, van den Elzen C, Verrips A, Bertine E, Muntoni F, Merlini L, Scheffer H, Brunner HG, Guicheney P, et al. 2006. The expanding phenotype of POMT1 mutations: from Walker-Warburg syndrome to congenital muscular dystrophy, microcephaly, and mental retardation. Hum Mutat. 27(5)453-459.
37. Winder SJ. 2001. The complexities of dystroglycan. Trends Biochem Sci. 26(2):118-124.
38. Yamada H, Shimizu T, Tanaka T, Campbell KP, Matsumura K. 1994. Dystroglycan is a binding protein of laminin and merosin in peripheral nerve. FEBS Lett. 352(1)49-53.
39. Yoshida-Moriguchi T, Yu L, Stalnaker SH, Davis S, Kunz S, Madson M, Oldstone MB, Schachter H, Wells L, Campbell KP. 2010. O-mannosyl phosphorylation of alpha-dystroglycan is required for laminin binding. Science. 327(5961):88-92.